As a rationale for the evaluation of losartan treatment, we first showed that patients with RDEB display increased TGF-β levels and activity in wounds, and in the circulation (Supplementary Fig S1) (Ng et al, 2012; Kuttner et al, 2013; Nystrom et al, 2013; Wang et al, 2013b; Odorisio et al, 2014). The gene discussed is TGFB1; the disease is recessive dystrophic epidermolysis bullosa.